THE ORAL GLP-1 BATTLE
Through 7 weeks:
$NVO Wegovy Pill: 66.7k total prescriptions
$LLY Foundayo: 16k total prescriptions
Wegovy Pill is currently at 146k weekly total prescriptions
Foundayo's weekly total prescriptions declined this past week 🤯
$HIMS
Canaccord note out on on $VERU (from earlier)
- BUY rating and $25 Price TGT
"Supply agreement with Novo Nordisk shows Big Pharma players in obesity are watching enobosarm play out clinically"
We view this as a significant event for the company as it shows that enobosarm has grabbed the attention of one of the two biggest players in obesity. We view the data produced to date in the previous Phase II trial as compelling and believe a SARM such as enobosarm added to a GLP-1 regimen could be a significant differentiator.
More deets + (Canaccord Genuity)
$VERU
Canaccord keeps a Buy rating on Veru (VERU) with a $25 price target after the company disclosed a supply agreement with Novo Nordisk (NVO) for Wegovy. The news is a "significant event" for Veru as it shows enobosarm has "grabbed the attention of one of the two players in obesity," the analyst tells investors in a research note. Canaccord views Veru's data to date as "compelling" and believes enobosarm could be a "significant differentiator." Shares of Veru are up 154%, or $3.43, to $5.68 in midday trading.
You posted a lot of bad info on HUBC bro… I like you as a trader but be cautious with that next time.. not blaming you but you pumped all those SC13Gs and was completely wrong… just be mindful more next time as you got a lot of people who respect your game
Purely technical traders always sell too early, because they have no conviction. They don't know what they own. Stock goes up +10-20% & they sell. Stock winds up +100-200% higher months later. The best stock-pickers are contextual: technicals, fundamentals & thematics in unison.